A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

@article{Ciuleanu2013API,
  title={A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.},
  author={Tudor Eliade Ciuleanu and C M Tsai and C Tsao and Janusz Milanowski and Domenico Amoroso and Dae Seog DS Heo and Harry J. M. Groen and Aleusandra Szczesna and C Chung and T-Y Chao and Gary Middleton and Ali Zeaiter and Ga{\"e}lle Klingelschmitt and Barbara Klughammer and Nicholas Thatcher},
  journal={Lung cancer},
  year={2013},
  volume={82 2},
  pages={276-81}
}
BACKGROUND Molecularly targeted agents for non-small cell lung cancer (NSCLC) can provide similar efficacy to chemotherapy without chemotherapy-associated toxicities. Combining two agents with different modes of action could further increase the efficacy of these therapies. The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…